NI201200181A - Métodos de terapia combinada para tratar enfermedades proliferativas - Google Patents
Métodos de terapia combinada para tratar enfermedades proliferativasInfo
- Publication number
- NI201200181A NI201200181A NI201200181A NI201200181A NI201200181A NI 201200181 A NI201200181 A NI 201200181A NI 201200181 A NI201200181 A NI 201200181A NI 201200181 A NI201200181 A NI 201200181A NI 201200181 A NI201200181 A NI 201200181A
- Authority
- NI
- Nicaragua
- Prior art keywords
- proliferative diseases
- combined therapy
- therapy methods
- treat proliferative
- therapy
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35233310P | 2010-06-07 | 2010-06-07 | |
| US201161446909P | 2011-02-25 | 2011-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201200181A true NI201200181A (es) | 2013-02-06 |
Family
ID=45098373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201200181A NI201200181A (es) | 2010-06-07 | 2012-12-06 | Métodos de terapia combinada para tratar enfermedades proliferativas |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20140155344A1 (enExample) |
| EP (2) | EP3056201A1 (enExample) |
| JP (3) | JP6031437B2 (enExample) |
| KR (1) | KR101850566B1 (enExample) |
| CN (2) | CN105832703A (enExample) |
| AU (2) | AU2011264590B2 (enExample) |
| BR (1) | BR112012031163A2 (enExample) |
| CA (1) | CA2801891C (enExample) |
| CO (1) | CO6670568A2 (enExample) |
| CR (1) | CR20120638A (enExample) |
| IL (2) | IL223190A0 (enExample) |
| MX (1) | MX2012014231A (enExample) |
| MY (1) | MY166014A (enExample) |
| NI (1) | NI201200181A (enExample) |
| NZ (1) | NZ707377A (enExample) |
| PH (1) | PH12012502399A1 (enExample) |
| RU (2) | RU2016103126A (enExample) |
| SG (2) | SG10201504590WA (enExample) |
| WO (1) | WO2011156119A1 (enExample) |
| ZA (1) | ZA201208820B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| KR20190062506A (ko) | 2005-02-18 | 2019-06-05 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| RU2433818C2 (ru) | 2005-08-31 | 2011-11-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества |
| CN101605535A (zh) | 2006-12-14 | 2009-12-16 | 阿布拉科斯生物科学有限公司 | 用包含紫杉烷的纳米颗粒基于激素受体状态治疗乳腺癌 |
| WO2008150532A1 (en) * | 2007-06-01 | 2008-12-11 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| LT2419732T (lt) | 2009-04-15 | 2020-03-10 | Abraxis Bioscience, Llc | Prionų neturinčios nanodalelių kompozicijos ir būdai |
| US9370494B2 (en) | 2010-03-26 | 2016-06-21 | Abraxis Bioscience, Llc | Methods for treating hepatocellular carcinoma |
| EP2552439B1 (en) | 2010-03-29 | 2022-07-20 | Abraxis BioScience, LLC | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| WO2011123395A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
| PH12012502380B1 (en) | 2010-06-04 | 2019-08-23 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
| EP3056201A1 (en) * | 2010-06-07 | 2016-08-17 | Abraxis BioScience, LLC | Combination therapy methods for treating proliferative diseases |
| EP2701731B1 (en) | 2011-04-28 | 2020-07-29 | Abraxis BioScience, LLC | Intravascular delivery of nanoparticle compositions and uses thereof |
| KR20250020688A (ko) | 2011-04-29 | 2025-02-11 | 셀렉타 바이오사이언시즈, 인크. | 항체 반응을 감소시키기 위한 관용원성 합성 나노운반체 |
| US9427477B2 (en) | 2011-05-09 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| TW201700103A (zh) | 2011-11-01 | 2017-01-01 | 西建公司 | 利用胞嘧啶核苷類似物之口服配方治療癌症的方法 |
| MX374915B (es) | 2011-12-14 | 2025-03-06 | Abraxis Bioscience Llc | Uso de excipientes polimericos para liofilizacion o congelacion de particulas. |
| AU2013327638B2 (en) | 2012-10-01 | 2018-06-14 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| AU2014262164B2 (en) * | 2013-05-03 | 2020-02-27 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
| MX2021005697A (es) * | 2013-05-03 | 2021-07-07 | Selecta Biosciences Inc | Suministro de inmunosupresores que tienen una vida efectiva especificada, farmacodinamica y antigeno para la induccion de tolerancia inmunitaria. |
| MX380597B (es) | 2014-06-13 | 2025-03-12 | Mayo Found Medical Education & Res | Composición con complejos de nanopartículas/anticuerpos de paclitaxel unidos a albúmina para usarse al tratar linfoma. |
| US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| WO2015195634A1 (en) * | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| CN106714826A (zh) | 2014-09-07 | 2017-05-24 | 西莱克塔生物科技公司 | 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物 |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| EP3226856A4 (en) | 2014-12-02 | 2018-07-11 | Celgene Corporation | Combination therapies |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| MX381140B (es) | 2015-06-29 | 2025-03-12 | Abraxis Bioscience Llc | Métodos para tratar tumores de células epitelioides. |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| CN105606824B (zh) * | 2016-01-28 | 2018-04-06 | 山东省药物研究院 | 晚期乳腺癌患者外周血循环肿瘤细胞Her‑2基因的检测方法 |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| US11878061B2 (en) | 2016-03-21 | 2024-01-23 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| WO2017165440A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| US11548946B2 (en) | 2016-09-01 | 2023-01-10 | Mayo Foundation For Medical Education And Research | Carrier-PD-L1 binding agent compositions for treating cancers |
| EP3506950A1 (en) | 2016-09-01 | 2019-07-10 | Mayo Foundation for Medical Education and Research | Methods and compositions for targeting t-cell cancers |
| US11427637B2 (en) | 2016-09-06 | 2022-08-30 | Mayo Foundation For Medical Education And Research | Methods of treating PD-L1 expressing cancer |
| EP3509643A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| KR20190066033A (ko) * | 2016-10-07 | 2019-06-12 | 아브락시스 바이오사이언스, 엘엘씨 | 담도암의 치료 방법 |
| CN110612122A (zh) | 2017-03-11 | 2019-12-24 | 西莱克塔生物科技公司 | 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物 |
| CN118649239A (zh) | 2017-10-03 | 2024-09-17 | 克里蒂泰克公司 | 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症 |
| SG11202009145PA (en) | 2018-03-20 | 2020-10-29 | Abraxis Bioscience Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| CN108498529A (zh) * | 2018-06-20 | 2018-09-07 | 福建师范大学 | 用于肿瘤预防治疗的DNA甲基转移酶抑制剂与cGAMP药物组合物 |
| EP3880191A4 (en) * | 2018-11-13 | 2022-08-10 | Yee, Amy | Compositions and methods of enhancing immunotherapies |
| WO2020243745A1 (en) | 2019-05-29 | 2020-12-03 | Nelum Corporation | Methods and uses for treating cancer |
| AU2020375810A1 (en) | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| US20230330123A1 (en) * | 2020-08-11 | 2023-10-19 | Auxilla Pharmaceuticals And Research Llp | A non-aqueous suspension of anticancer agent |
| TR202018770A2 (tr) * | 2020-11-23 | 2021-02-22 | Ankara Ueniversitesi | Platine Dirençli Over Kanseri Tedavisine Yönelik Yeni Bir İlaç Taşıyıcı Sistem |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| KR100904931B1 (ko) * | 1997-06-27 | 2009-06-29 | 아브락시스 바이오사이언스, 엘엘씨 | 나노 입자 및 그의 제조 방법 |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| SI1585548T1 (sl) * | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| US20050187148A1 (en) * | 2004-02-25 | 2005-08-25 | Yoshinori Naoe | Antitumor agent |
| AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| US20060069060A1 (en) * | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| NZ599464A (en) * | 2005-02-03 | 2014-03-28 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| KR20190062506A (ko) * | 2005-02-18 | 2019-06-05 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| NZ592132A (en) * | 2005-08-31 | 2012-12-21 | Abraxis Bioscience Llc | Composition comprising nanoparticles of docitaxel and a citrate |
| CA2626679C (en) * | 2005-11-04 | 2011-08-16 | Merck & Co., Inc. | Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies |
| WO2008028193A2 (en) * | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| ES2569477T3 (es) * | 2006-12-04 | 2016-05-11 | Novartis Ag | Combinación de un inhibidor de HDAC y un antimetabolito |
| EP3326630A3 (en) | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| MX339451B (es) * | 2008-04-03 | 2016-05-27 | Cognate 3 Llc | Composiciones y metodos para inmunoterapia. |
| AU2009234127B2 (en) | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| JP2011517683A (ja) | 2008-04-10 | 2011-06-16 | アブラクシス バイオサイエンス， エルエルシー | 疎水性タキサン誘導体の組成物およびその使用 |
| DK3692983T3 (da) * | 2008-05-15 | 2021-09-20 | Celgene Corp | Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf |
| US20100055047A1 (en) * | 2008-08-26 | 2010-03-04 | Yiyu Zou | Methods for treating bronchial premalignancy and lung cancer |
| ES2668837T3 (es) * | 2008-12-11 | 2018-05-22 | Abraxis Bioscience, Llc | Terapia de combinación que incluye un taxano y un agente terapéutico adicional |
| ES2577024T3 (es) * | 2009-08-25 | 2016-07-12 | Abraxis Bioscience, Llc | Terapia combinada con composiciones de nanopartículas de taxano e inhibidores de Hedgehog |
| WO2011123395A1 (en) * | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
| EP2552439B1 (en) * | 2010-03-29 | 2022-07-20 | Abraxis BioScience, LLC | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| RU2621640C2 (ru) * | 2010-06-02 | 2017-06-06 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| PH12012502380B1 (en) * | 2010-06-04 | 2019-08-23 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
| EP3056201A1 (en) * | 2010-06-07 | 2016-08-17 | Abraxis BioScience, LLC | Combination therapy methods for treating proliferative diseases |
| US9149455B2 (en) * | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) * | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
-
2011
- 2011-05-20 EP EP16153625.5A patent/EP3056201A1/en not_active Withdrawn
- 2011-05-20 KR KR1020137000228A patent/KR101850566B1/ko active Active
- 2011-05-20 BR BR112012031163A patent/BR112012031163A2/pt not_active Application Discontinuation
- 2011-05-20 EP EP11792867.1A patent/EP2575774A4/en not_active Withdrawn
- 2011-05-20 MY MYPI2012005255A patent/MY166014A/en unknown
- 2011-05-20 SG SG10201504590WA patent/SG10201504590WA/en unknown
- 2011-05-20 RU RU2016103126A patent/RU2016103126A/ru not_active Application Discontinuation
- 2011-05-20 CA CA2801891A patent/CA2801891C/en active Active
- 2011-05-20 JP JP2013514194A patent/JP6031437B2/ja active Active
- 2011-05-20 NZ NZ707377A patent/NZ707377A/en unknown
- 2011-05-20 PH PH1/2012/502399A patent/PH12012502399A1/en unknown
- 2011-05-20 CN CN201610059985.4A patent/CN105832703A/zh active Pending
- 2011-05-20 RU RU2012156903/15A patent/RU2577278C2/ru active
- 2011-05-20 US US13/701,001 patent/US20140155344A1/en not_active Abandoned
- 2011-05-20 AU AU2011264590A patent/AU2011264590B2/en active Active
- 2011-05-20 CN CN201180038243.9A patent/CN103037846B/zh active Active
- 2011-05-20 MX MX2012014231A patent/MX2012014231A/es unknown
- 2011-05-20 SG SG2012088001A patent/SG185798A1/en unknown
- 2011-05-20 WO PCT/US2011/037450 patent/WO2011156119A1/en not_active Ceased
-
2012
- 2012-11-22 IL IL223190A patent/IL223190A0/en unknown
- 2012-11-22 ZA ZA2012/08820A patent/ZA201208820B/en unknown
- 2012-12-06 NI NI201200181A patent/NI201200181A/es unknown
- 2012-12-14 CR CR20120638A patent/CR20120638A/es unknown
-
2013
- 2013-01-04 CO CO13001846A patent/CO6670568A2/es unknown
- 2013-03-01 US US13/782,992 patent/US20140170228A1/en not_active Abandoned
-
2016
- 2016-07-04 JP JP2016132221A patent/JP2016175947A/ja not_active Withdrawn
- 2016-11-28 US US15/361,851 patent/US20170181998A1/en not_active Abandoned
-
2017
- 2017-03-15 AU AU2017201757A patent/AU2017201757A1/en not_active Abandoned
-
2018
- 2018-02-16 JP JP2018025928A patent/JP2018087227A/ja active Pending
- 2018-08-10 US US16/101,027 patent/US20190167629A1/en not_active Abandoned
-
2019
- 2019-10-03 IL IL26980819A patent/IL269808A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201200181A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
| NI201200179A (es) | Métodos de tratamiento contra el cáncer pancreático | |
| CL2017003457A1 (es) | Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor. | |
| CR20120528A (es) | Métodos para tratar el cáncer | |
| BR112016012713A2 (pt) | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento | |
| BR112017011536A2 (pt) | terapias de combinação | |
| BR112017028132A2 (pt) | métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula | |
| CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
| NI201200030A (es) | Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas. | |
| MX2015013355A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| CL2017000080A1 (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| MX380318B (es) | Nanoparticula que comprende rapamicina y albumina como agente anticancer. | |
| MX359413B (es) | Metodos de tratamiento de carcinoma hepatocelular. | |
| BR112012030699A2 (pt) | métodos para tratar câncer de bexiga | |
| MX2015011753A (es) | Metodos para tratar cancer de vegija. | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| BR112016007946A2 (pt) | combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer | |
| CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
| MX2018015916A (es) | Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer. | |
| ES2723778T3 (es) | Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos | |
| MX2018002681A (es) | Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1". | |
| BR112014032264A8 (pt) | Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
| HK1183814A (en) | Combination therapy methods for treating proliferative diseases |